Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Average Rating of “Moderate Buy” from Analysts
Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the five ...
BIO Stock Might Rise Following the Offer to Acquire Stilla
Bio-Rad offers to acquire all equity interests of Stilla Technology. The acquisition is expected to complement Bio-Rad's existing digital PCR portfolio.
Bio-Rad Laboratories (NYSE:BIO) Rating Lowered to Hold at StockNews.com
StockNews.com lowered shares of Bio-Rad Laboratories (NYSE:BIO – Free Report) from a buy rating to a hold rating in a research note issued to investors on Monday morning. Other analysts have also ...